Furthermore, lack of significant inhibition in the number of small lesions upon CD5-2 treatment suggests potentially that miR-27a/VE-cadherin may play a less important role in the initiation of CCM development than in the growth of CCM lesions. This evidence concerns the gene CD52 and cerebral cavernous malformation.